General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Business strategy

A global leader in healthcare, Novartis is uniquely positioned to take advantage of the fast-changing industry environment and to fulfill its mission of caring and curing. As we enter our next growth phase, we are accelerating the execution of our strategy of leading through science-based innovation to deliver positive health outcomes for patients and payers. Our strategic priorities are to extend our lead in innovation, accelerate growth and drive productivity across our diversified portfolio in order to generate profits and increase shareholder return. Committed to high performance with integrity, we are engaged in an open and cooperative dialogue with all of our stakeholders.

Extending lead in innovation: Science-based innovation is at the heart of Novartis. We follow a distinct research and clinical approach to build an industry-leading pipeline of differentiated medicines and treatments with the goal of delivering real-world benefits to patients and healthcare providers.

Accelerating growth: Novartis is pursuing long-term growth by maximizing product launches and leveraging its robust portfolio. We are expanding in established and emerging markets and adapting our commercial model to the rapidly changing healthcare environment.

Driving productivity: Novartis is driving productivity by simplifying its processes, accelerating cross-divisional collaboration, and improving global procurement and supply chain management. We are using rigorous resource allocation to improve cash management and profitability.

Our four strategic enablers allow us to pursue high performance with integrity.

Commitment to people: We strive to attract and retain the best talent in the industry, nurture team diversity and cultivate high engagement.

Quality beyond compliance: We are dedicated to producing high-quality pharmaceutical and medical therapies that exceed industry standards to protect patient safety and build trust with our stakeholders.

Ethical business practices: Through global adherence to our Code of Conduct, we consistently strive for the highest ethical standards around the world.

Corporate responsibility: We are committed to enhancing access to medicines and healthcare services for underserved populations through innovative patient support programs and Social Ventures.